

Genomic RNA from SARS-Related Coronavirus 2, Isolate Italy-INMI1

Catalog No. NR-52498

For research use only. Not for human use.

Contributor:

Maria R. Capobianchi, Ph.D., Lazzaro Spallanzani National Institute for Infectious Diseases (INMI), Rome, Italy

Manufacturer:

BEI Resources

Product Description:

Genomic RNA was extracted from a preparation of cell lysate and supernatant from *Cercopithecus aethiops* kidney epithelial cells (Vero E6; ATCC® CRL-1586™) infected with severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), isolate Italy-INMI1.

SARS-CoV-2, isolate Italy-INMI1 was isolated from sputum of a patient with a respiratory illness who had recently returned from travel to the affected region of China and developed clinical disease (COVID-19) in January 2020 in Rome, Italy.^{1,2} The complete genome of SARS-CoV-2, Italy-INMI1 has been sequenced (GenBank: [MT066156](https://www.ncbi.nlm.nih.gov/nuccore/MT066156)).³

Material Provided:

Each vial contains approximately 100 µL of viral genomic RNA in TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 7.0). The viral genomic RNA is in a background of cellular nucleic acid and carrier RNA. The vial should be centrifuged prior to opening.

Packaging/Storage:

NR-52498 was packaged aseptically in screw-capped plastic cryovials. The product is provided frozen on dry ice and should be stored at -60°C or colder immediately upon arrival. Freeze-thaw cycles should be minimized.

Citation:

Acknowledgment for publications should read “The following reagent was obtained from Dr. Maria R. Capobianchi through BEI Resources, NIAID, NIH: Genomic RNA from SARS-Related Coronavirus 2, Isolate Italy-INMI1, NR-52498.”

Biosafety Level: 2

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 5th ed. Washington, DC: U.S. Government Printing Office, 2009; see www.cdc.gov/biosafety/publications/bmbl5/index.htm.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the Emergency Use Simple Letter Agreement (EUSLA) and the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

SARS-CoV-2 materials provided by BEI Resources under the EUSLA are made available for any legitimate purpose, including commercial purposes as long as they are to rapidly prevent, detect, prepare for, and respond to, the spread or transmission of the 2019 SARS-CoV-2. Any further transfer of the original material or any unmodified progeny must be done under the terms of the EUSLA, documented as described above and you must notify BEI Resources of each subsequent transfer. Any new materials made by you that are not the original material or unmodified progeny are excluded from this requirement and you are free to share and commercialize those as your materials.

References:

1. Capobianchi, M. R., Personal Communication.
2. Colavita, F., et al. “SARS-CoV-2 Isolation from Ocular Secretions of a Patient with COVID-19 in Italy with Prolonged Viral RNA Detection.” Ann. Intern. Med. (2020): doi: 10.7326/M20-1176. PubMed: 32302380.
3. Capobianchi, M. R., et al. “Molecular Characterization of SARS-CoV-2 from the First Case of COVID-19 in Italy.” Clin. Microbiol. Infect. (2020): doi: 10.1016/j.cmi.2020.03.025. PubMed: 32229288.

ATCC® is a trademark of the American Type Culture Collection.

